Gene Symbol | APOBEC3F |
---|---|
Entrez Gene | 200316 |
Alt Symbol | A3F, ARP8, BK150C2.4.MRNA, KA6 |
Species | Human |
Gene Type | protein-coding |
Description | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F |
Other Description | DNA dC->dU-editing enzyme APOBEC-3F|apolipoprotein B editing enzyme catalytic polypeptide-like 3F|apolipoprotein B mRNA editing enzyme cytidine deaminase|apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F|induced upon T-cell activation |
Swissprots | B0QYD4 Q7Z2N5 Q6ICH3 Q45F03 Q7Z2N2 Q8IUX4 |
Accessions | AAZ38720 EAW60288 EAW60289 Q8IUX4 AK294810 BAG57929 BC038808 AAH38808 BE888653 BE892372 BG280786 BG744406 BG758984 BM681311 BQ056344 BQ182066 BQ941658 BX367450 CR456395 CAG30281 CU012953 CAK54384 CU013241 CAK54683 CX165430 DA221480 JF262037 AEA39617 KC329530 AGI04218 U38435 XM_011529994 XP_011528296 NM_001006666 NP_001006667 NM_145298 NP_660341 |
Function | DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination- independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double- stranded RNA. Exhibits antiviral activity also against hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV- |
Subcellular Location | Cytoplasm. Cytoplasm, P-body. |
Tissue Specificity | Widely expressed. Highly expressed in ovary. {ECO:0000269|PubMed:11863358, ECO:0000269|PubMed:15152192, ECO:0000269|PubMed:20308164}. |
Human APOBEC3F full length protein - ab132966 from Abcam
|
||||||||||
Human APOBEC3F protein fragment - ab165861 from Abcam
|
||||||||||
APOBEC3F / ARP8 Antibody Blocking Peptide - LS-E14657 from LifeSpan Bioscience
|
||||||||||
APOBEC3F / ARP8 Antibody Blocking Peptide - LS-E14656 from LifeSpan Bioscience
|
||||||||||
APOBEC3F / ARP8 Antibody Blocking Peptide - LS-E9985 from LifeSpan Bioscience
|
||||||||||
APOBEC3F / ARP8 Antibody Blocking Peptide - LS-E15109 from LifeSpan Bioscience
|
||||||||||
Recombinant Human APOBEC3F Protein - H00200316-P01 from Novus Biologicals
|
||||||||||
Recombinant Human APOBEC3F Protein - H00200316-Q01 from Novus Biologicals
|
||||||||||
APOBEC3F-Antibody-N-term-Blocking-Peptide - BP9176a from Abgent, a WuXi AppTec company
|
||||||||||
ApoBEC3F Blocking Peptide - 33R-6629 from Fitzgerald
|
||||||||||
ApoBEC3F Blocking Peptide - 33R-6157 from Fitzgerald
|
||||||||||
ApoBEC3F Blocking Peptide - 33R-1538 from Fitzgerald
|
||||||||||
APOBEC3F - H00200316-P01-10 from Acris Antibodies
|
||||||||||
APOBEC3F - H00200316-P01-25 from Acris Antibodies
|
||||||||||
APOBEC3F - H00200316-Q01-10 from Acris Antibodies
|
||||||||||
APOBEC3F - H00200316-Q01-25 from Acris Antibodies
|
||||||||||
Recombinant Human DNA dC->dU-editing enzyme APOBEC-3F(APOBEC3F) - CSB-YP816878HU CSB-EP816878HU CSB-BP816878HU CSB-MP816878HU from Cusabio
|
||||||||||
APOBEC3F Protein - abx163678 from Abbexa
|
||||||||||
APOBEC3F (transcript variant 1) - TP307845 from Acris Antibodies
|
||||||||||
APOBEC3F Peptide, Human - M34GP00778H from Creative Peptides
|
||||||||||
DNA dC->dU-editing enzyme APOBEC-3F (APOBEC3F), Recombinant Protein - MBS1312704 from MyBioSource
|